RMT-Epigenomex, Inc.
Reducing Time & Cost for Drug Discovery




RMT's fundamental innovation focuses on the life sciences field of epigenetics which has been expanding rapidly and adding significant breakthroughs in our understanding of the regulation of human gene expression. 

About Us



RMT’s fundamental innovation focuses on the life sciences field of epigenetics. While we are not a drug development company, we partner with biotech and pharmaceutical companies, contract research organizations and academia to dramatically reduce the time and cost of new drug development.

 

A simple way to understand epigenetics is to think of the genome (DNA) as being a computer’s hardware and the epigenome (epigenetics) as the software that tells the computer how to work. Many in the scientific community have suggested that genome science by itself has failed to deliver on its early promise of new drug development. This is principally due to the fact that errors and mutations in genes result in a severely broken or defective system that is extremely difficult to repair with drugs or even with human genetic engineering. By comparison, the epigenome activates or represses human genes by mechanisms that place chemical marks called “methyl-groups” either directly on the DNA of genes or on protein molecules that attach to genes. These interactions with DNA regulate the gene program (expression of proteins).

 

The field of epigenetics has been expanding rapidly and adding significant breakthroughs in our understanding of the regulation of human gene expression. As a subset of the estimated $1.2 trillion pharmaceutical market, epigenetic chemical biology has emerged as a major market disruptor offering considerable advancements for disease diagnosis and the discovery of new drugs. RMT continues to build a patent portfolio that exploits the unique structural signature shared by most methylarginine proteins to facilitate drug discovery and significantly shorten the timeline of the development pipeline. The proprietary designs of RMT’s technology to determine protein methylation status require much less empirical adjustment and validation of the chemical and biological screening steps employed by other epigenetic drug discovery and development platforms, such as DNA methylation, lysine methylation, histone acetylation and others.

 

RMT’s technology lies in the area where methyl-groups are added to proteins in order to regulate gene programs. RMT focuses on methylarginine because it is one of the most significant types of methyl-group proteins, appearing on hundreds of protein targets that are involved in controlling gene programs.

 

As a Buffalo based company, RMT seeks to become a major influence in serving drug developers. The company’s technology is highly scalable, allowing it to influence multiple stages of the drug development process.  RMT is also focused on job creation and enhancing the reputation of SUNY at Buffalo as an incubator for novel and important medical innovation.